[Cu]Cu-ATSM: an Emerging Theranostic Agent for Cancer and Neuroinflammation
Overview
Nuclear Medicine
Radiology
Authors
Affiliations
Huang Y, Nishikawa Y, Mori T, Nogami M, Makino A, Kiyono Y Sci Rep. 2025; 15(1):7227.
PMID: 40021767 PMC: 11871321. DOI: 10.1038/s41598-024-85027-2.
Bifunctional Copper Chelators Capable of Reducing Aβ Aggregation and Aβ-Induced Oxidative Stress.
Krasnovskaya O, Abramchuk D, Vaneev A, Gorelkin P, Abakumov M, Timoshenko R ACS Omega. 2024; 9(43):43376-43384.
PMID: 39493999 PMC: 11525521. DOI: 10.1021/acsomega.4c03152.
Biomarker-driven molecular imaging probes in radiotherapy.
Li H, Gong Q, Luo K Theranostics. 2024; 14(10):4127-4146.
PMID: 38994026 PMC: 11234278. DOI: 10.7150/thno.97768.
Unveiling the promising anticancer effect of copper-based compounds: a comprehensive review.
Abdolmaleki S, Aliabadi A, Khaksar S J Cancer Res Clin Oncol. 2024; 150(4):213.
PMID: 38662225 PMC: 11045632. DOI: 10.1007/s00432-024-05641-5.
A Luciferase Reporter Assay to Detect Cellular Hypoxia In Vitro.
Inubushi M, Takeuchi Y, Murai C, Kitagawa Y Methods Mol Biol. 2024; 2755:77-89.
PMID: 38319570 DOI: 10.1007/978-1-0716-3633-6_5.